Planta Med 2013; 79 - SL52
DOI: 10.1055/s-0033-1351878

Influence of gut flora-derived ellagitannins' metabolites- urolithins on production and release of pro-inflammatory factors from stimulated neutrophils in the context of cardiovascular disease prevention

JP Piwowarski 1, S Granica 1, AK Kiss 1
  • 1Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Faculty of Pharmacy ul. Banacha 1, 02 – 097 Warsaw, Poland

Ellagitannin-rich products were proven to have beneficial influence on cardiovascular system [1 – 2]. Due to not well-established bioavailability of ellagitannins nowadays their gut flora derived metabolites- urolithins become a target in research of factors responsible for clinical effects. Because of the important role of neutrophils in the development of pathologies in cardiovascular system [3], the influence of urolithins A, B and C on their pro-inflammatory functions was tested. Urolithin B at concentration of 20µM showed significant inhibition of IL-1β, IL-8 and MMP-9 production induced by LPS (26.5 ± 6.2, 31.6 ± 1.7, 49.6 ± 7.7% respectively). Urolithin C was the only active compound towards inhibition of elastase release from cytochalasin A/f-MLP stimulated neutrophils. At concentration 5 and 20µM urolithin C decreased the elastase level by 39.0 ± 6.1 and 66.6 ± 2.9% respectively. Myeloperoxidase release was strongly inhibited by urolithin A and C (at 20µM by 46.7 ± 4.6 and 63.8 ± 3.1% respectively). Urolithin A was the strongest ROS release inhibitor both in f-MLP and PMA stimulated neutrophils. At the concentration of 1µM caused ROS level decrease by 42.6 ± 8.9 and 53.7 ± 5.4% respectively. Obtained results indicate, that urolithins can specifically modulate inflammatory functions of neutrophils, and thus at least partially explain observed beneficial effects of ellagitannin-rich food products, nutraceuticals and medicinal plants on cardiovascular system.


[1] Estruch, R., Ros, E., Salas-Salvado, J., Covas, M. I., et al., Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N. Engl. J. Med. 2013, 368, 1279 – 1290

[2] Larrosa, M., Garcia-Conesa, M. T., Espin, J. C., Tomas-Barberan, F. A., Ellagitannins, ellagic acid and vascular health. Mol. Aspects Med. 2010, 31, 513 – 539.

[3] Baetta, R., Corsini, A., Role of polymorphonuclear neutrophils in atherosclerosis: Current state and future perspectives. Atherosclerosis 2010, 210, 1 – 13.